Shares of Vor Biopharma Inc. (NYSE:VOR – Get Rating) have earned an average recommendation of “Moderate Buy” from the seven research firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $19.50.
A number of research firms have recently weighed in on VOR. Barclays lowered their target price on Vor Biopharma from $26.00 to $15.00 and set an “overweight” rating for the company in a research note on Friday, November 11th. Oppenheimer lowered their target price on Vor Biopharma from $27.00 to $18.00 and set an “outperform” rating for the company in a research note on Monday, November 14th. Finally, JMP Securities lowered their target price on Vor Biopharma from $15.00 to $12.00 and set a “market outperform” rating for the company in a research note on Thursday.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of VOR. Bourgeon Capital Management LLC grew its holdings in shares of Vor Biopharma by 39.0% during the 3rd quarter. Bourgeon Capital Management LLC now owns 10,700 shares of the company’s stock worth $43,000 after acquiring an additional 3,000 shares during the period. Corton Capital Inc. grew its holdings in shares of Vor Biopharma by 37.6% during the 2nd quarter. Corton Capital Inc. now owns 14,856 shares of the company’s stock worth $74,000 after acquiring an additional 4,061 shares during the period. Goldman Sachs Group Inc. grew its holdings in shares of Vor Biopharma by 48.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 25,607 shares of the company’s stock worth $155,000 after acquiring an additional 8,370 shares during the period. Jane Street Group LLC purchased a new position in shares of Vor Biopharma during the 3rd quarter worth approximately $41,000. Finally, Virtu Financial LLC purchased a new position in shares of Vor Biopharma during the 2nd quarter worth approximately $61,000.
Vor Biopharma Stock Down 3.9 %
Vor Biopharma (NYSE:VOR – Get Rating) last issued its quarterly earnings results on Thursday, November 10th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.03). As a group, research analysts expect that Vor Biopharma will post -2.38 EPS for the current fiscal year.
About Vor Biopharma
Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.
- Get a free copy of the StockNews.com research report on Vor Biopharma (VOR)
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
- Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
- Microsoft Layoffs Signal Layoffs for Other Tech Companies?
Receive News & Ratings for Vor Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vor Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.